Zydus Lifesciences (BOM:532321) Total Liabilities : ₹71,792 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Total Liabilities?

Zydus Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 was ₹71,792 Mil.

Zydus Lifesciences's quarterly Total Liabilities declined from Sep. 2023 (₹49,385.00 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹71,792.00 Mil).

Zydus Lifesciences's annual Total Liabilities declined from Mar. 2022 (₹87,416.00 Mil) to Mar. 2023 (₹60,681.00 Mil) but then increased from Mar. 2023 (₹60,681.00 Mil) to Mar. 2024 (₹71,792.00 Mil).

Zydus Lifesciences Total Liabilities Historical Data

The historical data trend for Zydus Lifesciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Total Liabilities Chart

Zydus Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

119,762.00

89,551.00

87,416.00

60,681.00

71,792.00

Zydus Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															60,681.00	-	49,385.00	-	71,792.00

Zydus Lifesciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zydus Lifesciences's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	53419	+	(251	+	18122
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	71,792

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	292808	-	221016
	=	71,792

Zydus Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	53419	+	(251	+	18122
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	71,792

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	292808	-	221016
	=	71,792

Zydus Lifesciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Total Liabilities

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines